Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Sea Limited (SE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Sea Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Sea Limited trades at $112 (market cap $68.07B). The key difference: Sea Limited is the larger of the two by market cap, and Sea Limited is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SE | |
|---|---|---|
Market Cap | $39.89B | $68.07B |
Sector | Health | Media |
52-Week High | $491.22 | $196.50 |
52-Week Low | $278.09 | $78.16 |
Enterprise Value | $38.15B | $61.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Sea Limited (SE) trades at $111.14, up 1.86% on the day, near its resistance level of $112. The stock shows strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarterly earnings have been mixed. Technical indicators are bullish on moving averages but show overbought conditions with RSI above 78. Analyst sentiment remains positive with a consensus price target of $131.
Outlook: Growth prospects are supported by expanding digital services in Southeast Asia, but risks include competitive pressures and execution challenges. The stock's high P/E of 43.76 suggests premium valuation, requiring sustained earnings growth to justify current levels. Near-term performance may hinge on Q2 2026 earnings versus expectations of $0.834 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
